Bacteriophages show promise as antimicrobial agents

Journal of Infection

Volumn 36, Issue 1, 1998, Pages 5-15

  Alisky, J ^a,c   Iczkowski, K ^b   Rapoport, A ^a   Troitsky, N ^d  

^a SAINT LOUIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b MAYO CLINIC   (United States)

^c UNIVERSITY OF IOWA HOSPITALS AND CLINICS   (United States)

^d NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANIMAL; ANTIBIOTIC RESISTANCE; BACTERIAL INFECTION; BACTERIOLYSIS; BACTERIOPHAGE; HUMAN; MOUSE; PHYSIOLOGY; REVIEW;

ANIMALS; BACTERIAL INFECTIONS; BACTERIOLYSIS; BACTERIOPHAGES; DRUG RESISTANCE, MICROBIAL; HUMANS; MICE;

EID: 0031611704     PISSN: 01634453     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0163-4453(98)92874-2     Document Type: Review

References (62)

1. Slopek S, Durlakowa I, Weber-Dabrowska B, Kucharewicz-Krukowska A, Dabrowski M, Bisikiewicz R. Results of bacteriophage treatment of suppurative bacterial infections. I. General evaluation of the results. Archivum Immunologiæae et Therapiæae Experimentalis 1983; 31: 267-291.
2. Tenover FC, Hughes JM. The challenges of emerging infectious diseases: development and spread of multiply-resistant bacterial pathogens. JAMA 1996; 275: 300-304.
3. Lonks JR, Medeiros AA. The growing threat of antibiotic-resistant Streptococcuspneumoniae. Med Clin N America 1995; 79: 523-535.
4. Murray BE. New aspects of antimicrobial resistance and the resulting therapeutic dilemmas. J Infect Dis 1991; 163: 1184-1194.
5. Hoffmann J, Cetron MS, Farley MM et al. The prevalence of drugresistant streptococcus pneumoniae in Atlanta. N Engl J Med 1995; 333: 481-486.
6. Pallares R, Linares J, Vadillo M et al. Resistance to penicillin and cephalosporin and mortality from severe pneumococcal pneumonia in Barcelona, Spain. N Engl J Med 1995; 333: 474-480.
7. Berkowitz FE. Antibiotic resistance in bacteria. South Med J 1995; 88: 797-804.
8. Jernigan DB, Cetron MS, Breiman RF. Minimizing the impact of drug-resistant streptococcus pneumoniae (DRSP): a strategy from the DRSP working group. JAMA 1996; 275: 206-209.
9. Chopra I, Hodgson J, Metcalf B, Poste G. New approaches to the control of infections caused by antibiotic-resistant bacteria: an industry perspective. JAMA 1996; 275: 401-404.
10. Plouffe JF, Breiman RF, Facklam RR. Bacteremia with streptococcus pneumonia: implications for therapy and prevention. JAMA 1996; 275: 194-198.
11. Rahman MA, Summerton J, Foster E et al. Antibacterial activity and inhibition of protein synthesis in Escherichia coli by antisense DNA analogs. Antisense Res Devel 1991; 1: 319-327.
12. Topley WWC, Wilson GS. The Principles of Bacteriology and Immunity. New York: William Wood & Company, 1929: 224-233.
13. Adams MH. Bacteriophages. New York: Interscience Publishers Inc., 1959: 1-12.
14. Brock TD. Milestones in Microbiology. Washington, D.C.: American Society for Microbiology, 1961: 157-159.
15. Raiga-Clemenceau A. Le bacteriophage de d'Herelle et son pouvoir therapeutic. [d'Herelle's bacteriophage and its therapeutic power]. [French] Semaine des Hopitaux Therapeutique 1974; 50: 229-231.
16. Dixon B. Bacteriophage therapy. B M J Clinical Research Ed 1987; 294: 1168.
17. Kaczkowski H, Weber-Dabrowska B, Dabrowski M, Zdrojewicz Z, Cwioro F. Zastosowanie bakteriofagow w leczeniu przewleklych chorob bakteryjnych. [Use of bacteriophages in the treatment of chronic bacterial diseases]. [Polish] Wiadomosci Lekarskie 1990; 43: 136-141.
18. Slopek S, Durlakowa I, Weber-Dabrowska B, Kucharewicz-Krukowska A, Dabrowski M, Bisikiewicz R. Results of bacteriophage treatment of suppurative bacterial infections. II. Detailed evaluation of the results. Archivum Immunologiæ ; et Therapiæ Experimentalis 1983; 31: 295-327.
19. Slopek S, Durlakowa I, Weber-Dabrowska B, Dabrowski M, Kucharewicz-Krukowska A. Results of bacteriophage treatment of suppurative bacterial infections. III. Detailed evaluation of the results obtained in further 150 cases. Archivum Immunologiæ et Therapiæ Experimentalis 1984; 32: 317-335.
20. Slopek S, Kucharewicz-Krukowska A, Weber-Dabrowska B, Dabrowski M. Results of bacteriophage treatment of suppurative bacterial infections. IV. Evaluation of the results obtained in 370 cases. Archivum Immunologiæ et Therapiæae Experimentalis 1985; 33: 219-240.
21. Slopek S, Kucharewicz-Krukowska A, Weber-Dabrowska B, Dabrowski M. Results of bacteriophage treatment of suppurative bacterial infections. VI. Analysis of treatment of suppurative staphylococcal infections. Archivum Immunologiæ et Therapiæ Experimentalis 1985; 33: 241-259.
22. Slopek S, Kucharewicz-Krukowska A, Weber-Dabrowska B, Dabrowski M. Results of bacteriophage treatment of suppurative bacterial infections. VI. Analysis of treatment of suppurative staphylococcal infections. Archivum Immunologiæ; et Therapiæ Experimentalis 1985; 33: 261-273.
23. Slopek S, Weber-Dabrowska B, Dabrowski M, Kucharewicz-Krukowska A. Results of bacteriophage treatment of suppurative bacterial infections in the years 1981-1986. Archivum Immunologiæ; et Therapiæ Experimentalis 1987; 35: 569-583.
24. Cislo M, Dabrowski M, Weber-Dabrowska B, Woyton A. Bacteriophage treatment of suppurative skin infections. Archivum Immunologiæ et Therapiæ Experimentalis 1987; 35: 75-183.
25. Weber-Dabrowska B. Dabrowski M, Slopek S. Studies on bacteriophage penetration in patients subjected to phage therapy. Archivum Immunologies et Therapiæ Experimentalis 1987; 35: 563-568.
26. Kucharewicz-Krukowska A, Slopek S. Immunogenic effect of bacteriophage in patients subjected to phage therapy. Archivum Immunologiæ et Therapiæ Experimentalis 1987; 35: 553-561.
27. Chernomordik AB. Bakteriofagi i ikh lechebno-profilakticheskoe primenenie. [Bacteriophages and their therapeutic-prophylactic use]. [RUSSIAN] Meditsinskaia Sestra 1989; 48: 44-47.
28. Sakandelidze VM, Meipariani AN. Primenenie kombinirovannykh fagov pri gniono-vospalitel'nykh zabolevaniiakh [Use of combined phages in suppurative-inflammatory diseases]. (RUSSIAN] Zhurnal Mikrobiologii, Epidemiologii i Immunobiologii 1974; 51: 135-136.
29. Litvinova AM, Chtetsova VM, Kavtreva IG. K otsenkeeff ektivnosti primeneniia koli-proteinogo bakteriofaga pri dis'bakteriozakh kishechnika u novorozhdennykh nedonoshennykh detei. [Evaluation of efficacy of the use of coli-Proteus bacteriophage in intestinal dysbacteriosis in premature infants]. [RUSSIAN] Voprosy Okhrany Materinstva i Detstva 1979; 23: 42-44.
30. Tolkacheva TV, Abakumov EM, Martynova VA, Golosova TV. Korrektsiia disbakterioza kishechnika biologicheskimi preparatami u bol'nykh ostrymi leikozami. [Correction of intestinal dysbacteriosis with biological preparations in acute leukemia]. [RUSSIAN] Problemy Gematologii i Perelivaniia Krovi 1981; 26: 29-33.
31. Samsygina GA, Boni EG. Bakteriofagi i fagoterapiia v pediatricheskoi praktike. [Bacteriophages and phage therapy in paediatric practice]. [RUSSIAN] Pediatriia 1984; 4: 67-70.
32. Kochetkova VA. Mamontov AS, Moskovtseva RL et al. Fagoterapiia posleoperatsionnykh gnoino-vospalite'lnykh oslozhnenii u onkologicheskikh bo'lnykh. [Phagotherapy of postoperative suppurative-inflammatory complications in patients with, neoplasms]. [RUSSIAN] Sovetskaia Meditsina 1989; 6: 23-26.
33. Sakandelidze VM. Kompleksnoe primenenie spetsificheskikh fagov i antibiotikov pri razlichnykh infektsionnykh allergozakh. [The combined use of specific phages and antibiotics in different infectious allergoses]. [RUSSIAN] Vrachebno Delo 1991; 3: 60-63.
34. Miliutina LN, Vorotyntseva NV. Strategii i taktika etiotropnoi terapii ostrykh kishechnykh infektsii u detei na sovremennom etape. [Current strategy and tactics of etiotropic therapy of acute intestinal infections in children]. [RUSSIAN] Antibiotiki i Khimioterapiia 1993; 38: 46-53.
35. Smith HW, Huggins MB. Successful treatment of experimental Escherichia coli infections in mice using phage: its general superiority over antibiotics. J Gen Micr 1982; 128: 307-318.
36. Smith HW, Huggins MB. The association of the 018 K1 and H7 antigens and the ColV plasmid of a strain of Escherichia coli with its virulence and immunogenicity. J Gen Micr 1980; 121: 387-400.
37. Smith HW, Huggins MB. Effectiveness of phages in treating experimental Escherichia coli diarrhea in calves, piglets and lambs. J Gen Micr 1983; 129: 2659-2975..
38. Smith HW, Huggins MB, Shaw KM. The control of experimental Escherichia coli diarrhea in calves by means of bacteriophages. J Gen Micr 1987a; 133: 1111-1126.
39. Smith HW, Huggins MB, Shaw KM. Factors influencing the survival and multiplication of bacteriophages in calves and in their environment. J Gen Micr 1987b; 133: 1127-1135.
40. Soothill JS. Treatment of experimental infections of mice with bacteriophages. J Med Micr 1992; 37: 258-261.
41. Soothill JS. Bacteriophage prevents destruction of skin grafts by Pseudomonas aeruginosa. Burns 1994; 20: 209-211.
42. Geier MR, Trigg ME, Merril CR. Fate of bacteriophage lambda in non-immune germ-free mice. Nature 1973; 246: 221-222.
43. Merril CR, Biswas B, Carlton R et al. Long-circulating bacteriophage as antibacterial agents. Proc Natl Acad Sci USA 1996; 93: 3188-3192.
44. Kornstein LB, Waters VL, Cooper RC. A natural mutant of plasmid RP4 that confers phage resistance and reduced conjugative transfer. FEMS Microbial Letters 1992; 70: 97-100.
45. Biswas SK, Chowdhury R, Das J. A 14-kd inner membrane protein of Vibrio cholerae biotype el tor confers resistance to group IV choleraphage infection to classical vibrios. J Bact 1992; 174: 6221-6229.
46. Balakshina VV, Kulakov LA, Boronin AM. Dinamika vzaimodeistviia bakteriofaga phimF81 Pseudomonas aeruginosa s bakteriiami khoziiania, [Dynamics of the interaction between Pseudornonas aeruginosa bacteriophage FrnF81 and host bacteria], [RUSSIAN] Mikrobiologica 1992; 61: 1051-1055.
47. Coleman DC, Sullivan DJ, Russell RJ, Arbuthnott JP, Carey BF, Pomeroy HM. Staphylococcus aureus bacteriophages mediating the simultaneous lysogenic conversion of β-lysin staphylokinase and enterotoxin A: molecular mechanism of triple conversion. J Gen Micr 1989; 135: 1679-1697.
48. Reidl J, Mekalanos JJ. Characterization of Vibrio cholerae bacteriophage K139 and use of a novel mini-transposon to identify a phage-coded virulence factor. Molec Micr 1995; 18: 685-701.
49. Scotland SM, Gross RJ. Cheasty T. Rowe B. The occurrence of plasmids carrying genes for both enterotoxin production and drug resistance in Escherichia coli of human origin. J Hyg 1979; 83: 531-538.
50. Chausee MS, Liu J, Stevens DL, Ferretti JJ. Genetic and phenotypic diversity among isolates of Streptococcus pyogenes from invasive infections. J Inf Dis 1996; 173: 901-908.
51. Kapur V, Nelson K, Schlievert PM, Selander RK, Musser JM. Molecular population genetic evidence of horizontal spread of two alleles of the pyrogenic exotoxin C gene (speC) among pathogenic clones of Streptococcus pyogenes. Infect Immun 1992; 60: 3513-3517.
52. Zhou Y, Sugiyama H, Johnson EA. Transfer of neurotoxigenicity from Clostridium butyricum to a nontoxigenic Clostridlum botulinum type E-like strain. Appl Environ Microbiol 1993; 59: 3825-3831.
53. Wachsmuth K, Deboy J, Birkness K, Sack D, Wells J. Genetic transfer of antimicrobial resistance and enterotoxigenicity among Escherichia coll strains. Antimicrob Ag Chemother 1983; 23: 278-283.
54. Waldor MK, Mekalanos JJ. Lysogenic conversion by a filamentous phage encoding cholera toxin. Science 1996; 272: 1910-1914.
55. Takeda Y, Murphy JR. Bacteriophage conversions of heat-labile enterotoxins in Escherichia coli. J Bacterial 1978; 133: 278-283.
56. Beutin L, Geier D, Zimmerman S, Karch H. Virulence markers of Shiga-like toxin-producing Escherichia coli strains originating from healthy domestic animals of different species. J Clin Microbiol 1995; 33: 631-635.
57. Muhldorfer I, Hacker J, Keusch GT et al. Regulation of the Shigalike toxin II operon in Escherichia coli. Infect Immun 1996; 64: 495-502.
58. Yee AJ, DeGrandis S, Gyles CL. Mitomycin-induced synthesis of a Shiga-like toxin from enteropathogenic Escherichia coli H.I.8. Infect Immun 1993; 61: 4510-4513.
59. Paton AW, Paton JC, Heuzenroeder MW, Goldwater PN, Manning PA. Cloning and nucleotide sequence of a variant. Shiga-like toxin II gene from Escherichia coli 0X3 :H21 isolated from a case of sudden infant death syndrome. Microb Pathogen 1992; 13: 225-236.
60. Dickman S. Soviet science: a struggle for survival. Science 1991; 254: 1716-1719.
61. Aldhous P. Hard times for Polish industrial researchers. Nature 1991; 354: 341.
62. Kanin Y. Exodus likely to increase. Nature 1991; 354: 342-343.